Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$15.08M-87.47%Company Profile
- CEO
- Emmanuel Dulac PharmD, MBA
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 237
- Beta
- 1.34
- Country
- DK
Financials
Revenue
$15.08M-87.5%Net Income
$-181.04M-375.6%EBITDA
$-191.93M-388.2%Free Cash Flow
$-320.75M-426.6%EPS (diluted)
$-4.15-244.1%Shares Outstanding (diluted)
43.63M+91.3%Operating Expenses
$237.70MCash & Debt
$1.12BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2021 | $292.57M | $-1.02B | $-26.54 |
| 2020 | $353.31M | $-846.73M | $-22.07 |
| 2019 | $41.33M | $-571.54M | $-16.91 |
| 2018 | $37.98M | $581.28M | $18.94 |
| 2017 | $139.78M | $-272.27M | $-9.77 |
| 2016 | $234.78M | $-153.91M | $-6.33 |
| 2015 | $187.68M | $-113.96M | $-4.82 |
| 2014 | $153.77M | $-64.99M | $-2.87 |
| 2013 | $6.57M | $-183.68M | $-8.12 |
| 2012 | $223.56M | $36.37M | $1.61 |
| 2011 | $142.28M | $13.38M | $0.58 |
| 2010 | $87.36M | $-104.63M | $-4.58 |
| 2009 | $25.32M | $-75.71M | $-4.28 |
| 2008 | $56.26M | $-33.73M | $-1.91 |
Valuation
ZEALhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (18)
- Newsglobenewswire.com·21h ago·Positive
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026) Company announcement No. 53 / 2026 Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026) Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·5d ago·Negative
…e, with new findings from a body composition sub study of SYNCHRONIZE-1 also being presented.1,2,3 Copenhagen, Denmark, October 1, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…rational program with petrelintide monotherapy for chronic weight management has been initiated Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·7d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Company announcement No. 50 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 39, 2026) Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
…ntial to redefine the weight management experience for people living with obesity or overweight Copenhagen, Denmark, September 22, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·14d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Company announcement No. 49 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 38, 2026) Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·18d ago·Negative
…ard patients globally with active enrolment into the Phase 3 EASE-5 trial to support a U.S. NDA Copenhagen, Denmark, September 18, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·21d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Company announcement No. 48 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 37, 2026) Copenhagen, Denmark, September 14, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 47 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 10, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·28d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Company announcement No. 46 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 36, 2026) Copenhagen, Denmark, September 7, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·33d ago·Positive
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·35d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Company announcement No. 44 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, August 31, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 43 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 28, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·42d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Company announcement No. 41 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 34, 2026) Copenhagen, Denmark, August 24, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·49d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026) Company announcement No. 40 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 33, 2026) Copenhagen, Denmark, August 17, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Zealand Pharma Announces Financial Results for the First Half of 2026 Company announcement – No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy.
View source ↗ - Newsglobenewswire.com·56d ago·Positive
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
View source ↗
Earnings
Typical surprise +14.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 11$-11.04 vs $-5.84miss
- Thu, May 12$-5.16 vs $-6.61beat
- Thu, Nov 11$-4.61 vs $-6.31beat
- Thu, Aug 12$-1.11 vs $-5.77beat
- Wed, May 12$-5.78 vs $-6.17beat
- Thu, Mar 11$-9.76 vs $-5.90miss
Estimates and results for ZEAL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ZEAL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.